
TABLE OF CONTENTS



4.1 Envelope glycoprotein synthesis and glycosylation	16
4.2 Gp120 structure	16
4.3 Gp41 structure	23
5. HIV coreceptor usage and tropism	25
5.1 HIV coreceptor usage	25
5.2 Definition of HIV tropism	26
PART II. Genetic variability of HIV	29
1. Classification of HIV	29
1.1 HIV types	29
1.2 HIV type 1	29
1.3 HIV type 2	35
2. Global distribution of HIV-1 strains	35
3. Mechanisms of genetic diversity	36
3.1 High mutation rate of reverse transcriptase	36
3.2 High replication rate of HIV	37
3.3 Recombination	37
4. Implications of HIV variability	44
4.1 Transmission and disease progression	44
4.2 Diagnostics	45
4.3 Antiretroviral therapy	46
PART III. Neutralizing antibody against HIV infection 1. Antibody responses to HIV infection	48 48
2. Mechanisms of antibody-mediated protection	49
3. HIV-1 neutralizing monoclonal antibodies	53
4. Primate challenge models and passive immunization	54
5. Viral strategies to avoid neutralizing antibodies	55
PART IV. Mother-to-child transmission of HIV	57
1. Current situation	57

xiii

2. Timing and mechanisms	58
2.1 <i>In utero</i> transmission	58
2.1.1 Morphology of the human placenta	58
2.1.2 Mechanism of HIV <i>in utero</i> transmission	61
2.2 Intrapartum transmission	63
2.3 Postpartum transmission	64
3. Risk factors	66
3.1 Maternal factors	66
3.2 Obstetrical factors	68
3.3 Neonatal factors	68
4. Prevention of mother-to-child transmission of HIV	68
4.1 Antiretroviral therapy	68
4.2 Mode of delivery	69
4.3 Breastfeeding interventions	70
4.4 Others interventions	71
CHAPTER 2 : STUDY WORKS	72
1. INTRODUCTION	72
2. OBJECTIVES OF THE ENTIRE STUDY	73
3. MATERIALS AND METHODS, RESULTS, DISCUSSION	74
I. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission in Thailand	74 -
 Background and specific aims Materials and methods 	-74 75
All 3. Results ghts reserve	80
4. Discussion	86
5. Publications	87
II. Characteristics of human immunodeficiency virus type 1 (HIV-1) gp120 env sequences in mother-child pairs infected with HIV-1 subtype CRF01_AE	89

1. Background and specific aims	89
2. Materials and methods	90
3. Results	92
4. Discussion	102
5. Publications	104
III. Intrapatient Recombination between Human Immunodeficiency Virus Type 1 Envelope Cones in Mother to Child Transmission	115
Virus Type 1 Envelope Genes in Mother-to-Child Transmission	
1. Background and specific aims	115
2. Materials and methods	115
3. Results	118
4. Discussion	128
5. Publications	129
CHAPTER 3 : CONCLUSION AND PERSPECTIVES	130
1. CONCLUSION	130
2. PERSPECTIVES	132
CHAPTER 4 : RÉSUMÉ (SUMMARY IN FRENCH)	134
CHAFTER 4: RESUME (SUMMART IN FRENCH)	134
CHAPTER 5 : REFERENCES	138
Coppendix t [©] by Chiang Mai University	176
A PPENDIX A APPENDIX B hts reserve	e ¹⁷⁶ 179

CURRICULUM VITAE

XV

LIST OF TABLES

	. ગેમદાસંધ	
Table		Page
1	Potential mechanisms by which neutralizing and non- neutralizing Abs modulate the HIV life cycle	51
2 6	Baseline characteristics of transmitting and non-transmitting mothers	76
3	Comparison of detectable neutralizing antibodies against the 6 primary isolates in transmitting and non-transmitting mothers	81
4	Neutralizing antibody titers of 10 serum samples against LEA, MBA and V2MBA-Env Δ V2LEA pseudotyped viruses. Results are expressed as the reciprocal dilution that reduces the RLU by 50%	84
5	Samples used during the present study	116
6	Nucleic acid codes	176
7	Amino acid codes	177
8	Standard genetic code	178
ລິ້ມສໍາ	Different approaches to the use of ARV prophylaxis to prevent HIV infection in infants	180
Copyr	ARV prophylaxis regimens for PMTCT among pregnant women living with HIV who have not received antepartum therapy or prophylaxis	183
A 11	ARV prophylaxis regimens for infants born to women living with HIV who have not received antepartum or intrapartum therapy or prophylaxis	2185

xvii

LIST OF FIGURES

	. กมยนต์ .	
Figure	an 100 52	Page
1	Estimated number of people living with HIV globally during 1990-2007	4
2 6	Estimated number of adults and children to be living with HIV in 2007	5
3	Schematic representation of a mature HIV-1 virion (left) and a mature HIV-1 particle observed by electron cryotomography	7
4	Organization and landmarks of the HIV-1 DNA genome	8
5	Replication cycle of HIV-1	11
6	Schematic representation of the early steps of HIV-1 cell entry	12
7	Process of reverse transcription of HIV genome	14
8	Liner representation of the structure of HIV-1 envelope	17
9	Diagram of the structure of HIV-1 gp120 envelope glycoprotein	18
ຄືບຄື	Comparison of the conformation and molecular surface of deglycosylated liganded HIV-1 HXB2 gp120 core with glycosylated unliganded SIV gp120 core	19
Copyri	The HIV-1 gp120 structure Mai Universion	20-21
A 12	Diagram of the structure of HIV-1 gp41 envelope glycoprotein	e 24
13	V3 amino acid sequences and numbering according to HIV-1 HXB2	27

xviii

Fig	ure	Page
1	4 Model for HIV-1 coreceptor usage and tropism <i>in vivo</i>	28
1	5 Phylogenetic relationship of HIV-1 group M, N, O, and CRFs	31
1	6 The mosaic pattern of the CRFs available in HIV sequence database	33
1	7 Global distribution and prevalence of HIV-1 subtypes and recombinant forms	34
1	8 Type of HIV dual infection and plasma viral load at different clinical stages	38
1	9 The HIV recombination process	39-40
2	0 Forced copy-choice model	42
2	1 Strand displacement-assimilation model	43
2	2 The distribution of breakpoints across HIV-1 genome	44
2	3 Time cause of HIV infection	49
2	4 Steps at which antibodies can potentially interfere with HIV-1 replication	52
2	5 The epitopes for the broadly neutralizing mAbs on HIV-1 envelope glycoprotein	54
S 2	6 Comparison of the direct epitope variation and the glycan shield models of HIV-1 immune escape	56
	7 Percentage of women living with HIV from 1990 to 2007	58
Cop	8 Schematic representation of placenta structure	60-61
	9 Mechanisms of <i>in utero</i> transmission P C C P	$\mathbf{e}^{63}\mathbf{d}$
3	0 Origin of HIV in breast milk	65
3	1 Comparison of neutralizing antibody titers in transmitting (T) versus non-transmitting (NT) mothers	75


Figure

32	Construction of the V2 chimeric Envs	79
33	Comparison of neutralizing antibody titers in transmitting (T) and non-transmitting (NT) mothers	82
34	Locations of the sequence characteristics of the envelope glycoprotein of MBA	83
35	Effect of the V2 domain of MBA on the neutralization of LEA	85
36	Unrooted neighbor-joining tree of the 353 HIV-1 <i>env</i> gp120 nucleotide sequences from 17 mother-child pairs	93
37	Unrooted neighbor-joining trees of HIV-1 env gp120 nucleotide sequences for each mother-child pair	94-96
38	Characteristics of the viral variants in mothers and infants in all pairs $(n=17)$, in cases of in utero transmission only (n=6), and in cases of intrapartum transmission only (n=11).	98
39	Map of PNGS for each quasispecies present in either mother or infant	100- 101
40	Unrooted neighbor-joining trees of the 109 HIV-1 env gp120 nucleotide sequences from the two mother-child pairs	120- 123
41	Schematic representation of the recombination analysis for pairs 1005 and 0779	126
â 1 41	Alignment of HIV-1 env gp120 (V1-V5) amino acid consensus sequences of each group for pairs 1005 and	127
Copyri	1979t [©] by Chiang Mai Univer	sity
	rights reserv	e d

ABBREVIATIONS

		A918191 @
	Ab	Antibody
	ADCC	Antibody-directed cell-mediated cytotoxicity
	AIDS	Acquired immune deficiency syndrome
	APOBEC-3G	Apolipoprotein B mRNA editing enzyme, catalytic
		polypeptide-like 3G
	ART	Antiretroviral therapy
	ARV	AIDS-associated retrovirus
	ARV	Antiretroviral
9	C	Constant
5	CCR5	CC-chemokine receptor 5
	CD	Cluster of differentiation
	CD4BS	CD4-binding site
	CD4i	CD4-induced epitope
	CDC	Centers for Disease Control and Prevention
	CLR	Conditional logistic regression
	cpx	Complex
	CRFs	Circulating recombinant forms
	CTL	Cytotoxic T lymphocyte
	CXCR4	CXC-chemokine receptor 4
	DCs	Dendritic cells
	DC-SIGN	Dendritic cell specific ICAM-3 grabbing non-integrin
	DNA	Deoxyribonucleic acid
0	D-tropic	Dual-tropic
ลิปส์	Env	Envelope et a ser a se
	ER	Endoplasmic reticulum OLO OULTE
Con	gp	Glycoprotein
Сору		Human immunodeficiency virus
	HTLV HuMAbs	Human T-lymphotropic virus
	IDU	Human neutralizing monoclonal antibodies
	Ig	Immunoglobulin
	IQR	Inter-quartile range
	kDa	kilo Dalton
	LAV	Lymphadenopathy-associated virus

LTRLong terminal repeatMMajormAbMonoclonal antibodymm³Cubic millimeterMPERMembrane proximal external regionmRNAmessenger Ribonucleic acidMSMMet who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-nucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNSINon-nucleoside reverse transcriptase inhibitorsNSINon-nucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPheumocystis carinit pneumoniaPCRPolymerase chain reactionPHPTPerinatal HUP Prevention TrialPIProtease inhibitorsPMCSPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRSyncytium-inducingSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adapted </th <th></th> <th>LTNPs</th> <th>Long-term non-progressors</th>		LTNPs	Long-term non-progressors
MMajormAbMonoclonal antibodymm³Cubic millimeterMPERMembrane proximal external regionmRNAmessenger Ribonucleic acidMSMMen who have sex with menMTCTMother-to-thild transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-spectrumNRTISNucloside reverse transcriptase inhibitorsNRTISNucloside reverse transcriptase inhibitorsNRTISNucloside reverse transcriptase inhibitorsNRTISNon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPheumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIPretaese inhibitorsPMCHTPrevention of mother-child HIV transmissionPMGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRI.URelative luminescence unitRNARibonuclease HRTReverse transcriptasePMCSyncytium-inducingSIVSimian-human immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		LTR	
mAbMonoclonal antibodymm³Cubic millimeterMPERMembrane proximal external regionmRNAmessenger Ribonucleic acidMSMMen who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-nucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinit pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleica cidRNARibonucleica endRNASimian-human immunodeficiency virusSIVSimian immunodeficiency virusSVMSupervirum-inducingSIVSimian immunodeficiency virusSVMSupervirum-inducingSIVSimian immunodeficiency virusSVMSupervirum-inducingSIVSimian immunodeficiency virusSVMSupervirum-inducingSIVSimian immun		М	Major
mm³Cubic millimeterMPERMembrane proximal external regionmRNAmessenger Ribonucleic acidMSMMen who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-nucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCSPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrecention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelbonucleica cidRNARibonucleica cidRNASimian-human immunodeficiency virusSIVSimian immunodeficiency virusSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		mAb	
mRNAmessenger Ribonucleic acidMSMMen who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNCSPottential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleica cidRNARibonucleica relationSHIVSimian-human immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		mm ³	
mRNAmessenger Ribonucleic acidMSMMen who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNcw, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTINucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNeutralizing antibodyNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPMCHTPrevention of mother-child HIV transmissionPMCSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleica cidRNARibonucleica cidRNASyncytium-inducingSIVSimian-human immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA			Membrane proximal external region
MSMMen who have sex with menMTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNHHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPNCSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleiase HRTReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRSyncytium-inducingSIVSimian-human immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		mRNA	
MTCTMother-to-child transmissionM-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-oucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseSHIVSimian-human immunodeficiency virusSVMSupport vector machinesTCIDs050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		MSM	
M-tropicMacrophage-tropicNNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTISNon-nucleoside reverse transcriptase inhibitorsNRTISNucleoside reverse transcriptase inhibitorsNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURclative luminescence unitRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseSISyneytium-inducingSIVSimian-human immunodeficiency virusSVMSupport vector machinesTCIDs050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		MTCT	
NNew, or non-M, non-ONAbNeutralizing antibodyNIHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPoetnial N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonucleic acidRNASimian-human immunodeficiency virusSISyncytum-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA			Macrophage-tropic
NAbNeutralizing antibodyNIHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNAse HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseSISyncytum-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA			
NIHNational Institutes of HealthNNRTIsNon-nucleoside reverse transcriptase inhibitorsNRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleica cidRNARibonucleica cidRNASyneytium-inducingSISyneytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		NAb	
NRTISNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonucleica acidRTReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRSyncytium-inducingSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		NIH	
NRTIsNucleoside reverse transcriptase inhibitorsNSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonucleica acidRTPCRReverse transcriptaseRT-PCRReverse transcriptaseRT-PCRSyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	9	NNRTIs	Non-nucleoside reverse transcriptase inhibitors
NSINon-syncytium-inducingNVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	.5	NRTIs	
NVPNevirapineOOutlierPBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyneytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	9	NSI	
PBMCsPeripheral blood mononuclear cellsPCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPCRPerinatal HIV Prevention TrialPIPertease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNAse HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseRIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		NVP	
PCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		0	Outlier
PCPPneumocystis carinii pneumoniaPCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptaseSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		PBMCs	Peripheral blood mononuclear cells
PCRPolymerase chain reactionPHPTPerinatal HIV Prevention TrialPIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonucleic acidRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		РСР	
PIProtease inhibitorsPMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNARibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		PCR	Polymerase chain reaction
PMCHTPrevention of mother-child HIV transmissionPNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		РНРТ	Perinatal HIV Prevention Trial
PNGSPotential N-linked glycosylation sitesPSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID5050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		PI	Protease inhibitors
PSSMPosition-specific scoring matrixRFRandom forestRLURelative luminescence unitRNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		РМСНТ	Prevention of mother-child HIV transmission
RFRandom forestRLURelative luminescence unitRNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		PNGS	Potential N-linked glycosylation sites
RLURelative luminescence unitRNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		PSSM	Position-specific scoring matrix
RNARibonucleic acidRNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		RF	Random forest
RNase HRibonuclease HRTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		RLU	Relative luminescence unit
RTReverse transcriptaseRT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	6 1 8	RNA	Ribonucleic acid
RT-PCRReverse transcriptase-polymerase chain reactionSHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	ada	RNase H	Ribonuclease H
SHIVSimian-human immunodeficiency virusSISyncytium-inducingSIVSimian immunodeficiency virusSVMSupport vector machinesTCID ₅₀ 50% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		RT	Reverse transcriptase
SI SIVSyncytium-inducing Simian immunodeficiency viruse r v e dSVMSupport vector machinesTCID5050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	Copy	RT-PCR	Reverse transcriptase–polymerase chain reaction
SIVSimian immunodeficiency virusSVMSupport vector machinesTCID5050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA	COPI	SHIV	Simian-human immunodeficiency virus
SVMSupport vector machinesTCID5050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		SI	Syncytium-inducing
TCID5050% tissue culture infectious doseTCLAT-cell line-adaptedtRNAtransfer RNA		SIV	Simian immunodeficiency virus
TCLAT-cell line-adaptedtRNAtransfer RNA		SVM	Support vector machines
tRNA transfer RNA		TCID ₅₀	50% tissue culture infectious dose
			-
T-tropic T-cell line-tropic		tRNA	transfer RNA
		T-tropic	T-cell line-tropic



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่ Copyright[©] by Chiang Mai University All rights reserved

xxii